Publication:
Musculoskeletal senescence: a moving target ready to be eliminated

Simple item page
dc.contributor.authorBaar, Marjolein P.
dc.contributor.authorPerdiguero, Eusebio
dc.contributor.authorMunoz-Canoves, Pura
dc.contributor.authorde Keizer, Peter L. J.
dc.contributor.funderDutch Cancer Society (Holanda)
dc.contributor.funderUnión Europea. Comisión Europea
dc.contributor.funderMinisterio de Economía y Competitividad (España)
dc.contributor.funderUnión Europea. Comisión Europea. European Research Council (ERC)
dc.date.accessioned2018-11-05T11:58:22Z
dc.date.available2018-11-05T11:58:22Z
dc.date.issued2018
dc.description.abstractAging is the prime risk factor for the broad-based development of diseases. Frailty is a phenotypical hallmark of aging and is often used to assess whether the predicted benefits of a therapy outweigh the risks for older patients. Senescent cells form as a consequence of unresolved molecular damage and persistently secrete molecules that can impair tissue function. Recent evidence shows senescent cells can chronically interfere with stem cell function and drive aging of the musculoskeletal system. In addition, targeted apoptosis of senescent cells can restore tissue homeostasis in aged animals. Thus, targeting cellular senescence provides new therapeutic opportunities for the intervention of frailty-associated pathologies and could have pleiotropic health benefits.
dc.description.peerreviewedSí
dc.description.sponsorshipThe authors acknowledge support for MB from Dutch Cancer Society Grant UMCIJ-7141 awarded to PdK, and for EP and PMC from ERC-2016-AdG-741966 (STEM-AGING), SAF2015-67369-R, MDA and AFM. The DCESX/UPF is recipient of a `Maria de Maeztu' Program for Units of Excellence in R\&D MDM-2014-0370 (Government of Spain).
dc.format.page147-155
dc.format.volume40
dc.identifierISI:000438324100023
dc.identifier.citationCurr Opin Pharmacol. 2018; 40:147-155
dc.identifier.doi10.1016/j.coph.2018.05.007
dc.identifier.e-issn1471-4973
dc.identifier.issn1471-4892
dc.identifier.journalCurrent Opinion in Pharmacology
dc.identifier.pubmedID29883814
dc.identifier.urihttp://hdl.handle.net/20.500.12105/6580
dc.language.isoeng
dc.publisherElsevier
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/MINECO//SAF2015-67369-R/ES/ESTUDIO DEL DECLIVE DE LA REGENERACION MUSCULAR CON EL ENVEJECIMIENTO/
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/H2020/741966/EUes_ES
dc.relation.publisherversionhttps://doi.org/10.1016/j.coph.2018.05.007
dc.repisalud.institucionCNIC
dc.repisalud.orgCNICCNIC::Grupos de investigación::Laboratorio de Regeneración Tisular
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectMESENCHYMAL STEM-CELLS
dc.subjectSKELETAL-MUSCLE REGENERATION
dc.subjectMARROW STROMAL CELLS
dc.subjectCELLULAR SENESCENCE
dc.subjectSATELLITE CELLS
dc.subjectKNEE OSTEOARTHRITIS
dc.subjectARTICULAR-CARTILAGE
dc.subjectPROGENITOR CELLS
dc.subjectDNA-DAMAGE
dc.subjectPOSTTRAUMATIC OSTEOARTHRITIS
dc.titleMusculoskeletal senescence: a moving target ready to be eliminated
dc.typejournal article
dc.type.hasVersionVoR
dspace.entity.typePublication
relation.isAuthorOfPublication6ed362fa-f3ef-4758-9f08-c292f71128ec
relation.isAuthorOfPublication.latestForDiscovery6ed362fa-f3ef-4758-9f08-c292f71128ec

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
MusculoskeletalSenescenceMoving _2018.pdf
Size:
853.94 KB
Format:
Adobe Portable Document Format
Download

Collections

Grupos de investigación